Entities / Company
Incepta Pharmaceuticals.
incepta
- Reports this week
- 1
- Active events
- 2
- Connections
- 224
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
Gone quiet
No new reports in 90+ days-
LENZ Therapeutics shares outperformed industry average over the past week, following company developments.Some support2 reports1 development inside
-
China's volume-based procurement policies are impacting pharmaceutical companies like Incepta and Envista.Some support1 report
-
Recursion Pharmaceuticals experienced a decline on June 21, 2025, which lagged the losses of the S&P 500. The company was also placed into an industry group.Speculative1 report
-
Tilray Brands, Inc. showed higher growth than S&P 500 on June 21, 2025, and outperformed industry averages in short-term price activity.Speculative1 report
-
Viking Therapeutics and Incepta Pharmaceuticals are facing market scrutiny as their stock performance is compared against the S&P 500 and broader medical sector trends.Speculative1 report
-
Incepta Pharmaceuticals, Ensign Records, and Boston Scientific were classified into various medical industry groups in June 2025.Speculative1 report
-
On June 26, 2025, the Medical sector gain outperformed Humacyte's stock drop, with the cause traced to changes in the Zacks rating system.Speculative1 report
-
Siga Technologies stock underperformed the S&P 500 gain but led the Medical sector gain on July 25, 2025.Some support7 reports
-
HSIC's Price-to-Earnings ratio was reported to be lower than the industry average on June 30, 2025.Speculative1 report
-
Companies like Akero Therapeutics, Inc., Incepta Pharmaceuticals, and Aveanna Healthcare are noted for outperforming peers in the Medical sector.Some support6 reports2 developments inside
-
DaVita HealthCare outperformed S&P 500 daily loss and gained on the broader medical sector on July 2, 2025.Speculative1 report
-
Bayer Aktiengesellschaft and Dexcom were classified within the Large Cap Pharmaceuticals and Medical sectors, with Dexcom showing strong performance.Speculative1 report1 development inside
-
Amgen's monthly gain underperformed the Medical sector's gain, while operating in the biomedical and genetics industry.Speculative2 reports
-
Anavex Life Sciences (AVXL) received a Momentum Style Score of A and a Zacks Rank of #2 on July 11, 2025.Some support1 report
-
Incepta Pharmaceuticals and Molina Healthcare were ranked in the bottom 33% of the industry as of July 12, 2025.Some support1 report
-
On July 12, 2025, Moderna's stock drop lagged the S&P 500's daily loss, while the company outperformed the losses of the broader medical sector.Some support4 reports
-
Incepta Pharmaceuticals and West Pharmaceutical Services operate within the medical supplies sector.Some support3 reports1 development inside
-
Incepta Pharmaceuticals and Delcath Systems, Inc. are involved in a new industry ranking.Some support1 report
-
Incepta Pharmaceuticals, BioNTech SE Sponsored ADR, and EUROFINS SCIENT were noted for outperforming their peers in the Medical sector on July 24, 2025.Some support1 report
-
Cardiff Oncology, a company in the medical/biomedical sector, underperformed the broader market index on July 30, 2025.Some support1 report
-
Incepta Pharmaceuticals and Amphastar Pharmaceuticals were ranked in the Generic Drugs industry.Some support1 report2 developments inside
-
Kiniksa Pharmaceuticals International, plc (KNSA) shares outperformed industry peers significantly on August 6, 2025.Some support1 report
-
Fortrea Holdings Inc. was noted for underperforming the market index this year, while Incepta Pharmaceuticals belongs to the relevant industry sector.Some support4 reports
-
Phathom Pharmaceuticals, which operates in the Zacks Medical - Biomedical and Genetics industry, has been noted for underperforming the S&P 500 so far this year.Some support1 report
-
Seer, Inc., a biomedical company, underperformed the S&P 500 this year, operating within the sector while Zacks Rank tracks earnings revisions.Some support1 report
-
The company, Incepta Pharmaceuticals, was noted to belong to a specific industry as of August 7, 2025.Some support1 report
-
AnaptysBio outperformed the market index on August 7, 2025, while the company was noted to be in a specific industry sector.Some support2 reports
-
Incepta Pharmaceuticals and Niagen Bioscience outperformed market gains this year, with investors using Zacks Rank to track earnings revisions.Some support1 report
-
Urogen Pharma was classified in the Zacks Medical - Biomedical and Genetics industry and outperformed the S&P 500 stock gain this year.Some support1 report
-
Eton Pharmaceuticals outperformed the S&P 500 this year and belongs to the relevant industry.Some support1 report
-
Generation Bio Co. underperformed the market index while Incepta Pharmaceuticals was noted as being in the relevant industry sector.Some support1 report
-
On August 13, 2025, the Price-to-Earnings ratio of Incepta Pharmaceuticals was noted to match that of Cardinal Health.Some support1 report
-
Incepta Pharmaceuticals and Novavax were mentioned in a report on August 13, 2025, noting that industry performance influences stock trends.Some support1 report
-
Incepta Pharmaceuticals and BioCryst Pharmaceuticals were ranked in the Medical – Drugs industry as of August 13, 2025.Some support1 report
-
Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.Some support1 report
-
On August 13, 2025, Orchestra BioMed Holdings, Inc. underperformed market gains while Incepta Pharmaceuticals was noted as being in the relevant industry sector.Some support1 report
-
Alpha Cognition Inc. outperformed the market index on August 15, 2025, and investors can rely on Zacks Rank for tracking revisions.Some support2 reports
-
Black Diamond Therapeutics and BioRestorative Therapies, Inc. showed strong stock performance compared to the medical sector average in August 2025.Some support1 report
-
Incepta Pharmaceuticals and Hologic are companies, with Hologic operating in the Medical - Instruments industry.Some support2 reports
-
Incepta Pharmaceuticals and Becton Dickinson were ranked in an industry as of August 2025.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Incepta Pharmaceuticals this week
News at the entities that move Incepta Pharmaceuticals most-
Bangladesh Shared contextUS diplomatic pressure and WFP humanitarian aid are deployed in Bangladesh regarding the Rohingya crisis.Moves Incepta Pharmaceuticals
-
Boston Scientific OperationalIntuitive Surgical, Boston Scientific, and Abbott Laboratories are major players in the global healthcare device sector.Moves Incepta Pharmaceuticals
-
Encompass Health Mentioned togetherTrump pledged to unleash American oil and gas, while also discussing share price versus business value with Paylocity and Warren Buffett.Moves Incepta Pharmaceuticals
-
Atai Life Sciences Shared contextAtai Life Sciences, a German-headquartered company, is seeking FDA meetings and study results while benefiting from Trump-era tariffs.Moves Incepta Pharmaceuticals
-
Cue Mentioned togetherCue, an Australian fashion brand, has opened its first store in Sydney.Moves Incepta Pharmaceuticals
-
HCA Corporation Mentioned togetherHCA Corporation provides medical services in the US and England, while also operating in finance, manufacturing tobacco products, and facilitating U.S.-Asia cross-border transactions.Moves Incepta Pharmaceuticals
Connections
The 22 strongest of 224, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novavax Mentioned together
Both Incepta Pharmaceuticals and Novavax are categorized within the medical sector.
-
SIGA Technologies Shared context
Both companies operate within the shared context of the Medical - Drugs industry sector.
-
Encompass Health Mentioned together
Both companies are discussed within the same healthcare sector and noted for outperforming industry returns.
-
Humacyte (United States) Shared context
Both Incepta Pharmaceuticals and Humacyte operate within the broader medical sector.
-
Boston Scientific Operational
Both companies operate in the medical products sector and are identified as competitors.
-
Atai Life Sciences Shared context
Atai Life Sciences and Incepta Pharmaceuticals share the same pharmaceutical industry context.
-
Cue Mentioned together
Both companies are co-mentioned in the context of shared industry outlook impacting stock performance.
-
Amphastar Pharmaceuticals Mentioned together
Both companies are identified as operating within the generic drugs sector.
Show all 22 connections
-
Bangladesh Shared context
The company operates within the country's economic and political framework, which is credited for its past growth.
-
IDEXX Laboratories, Inc. Mentioned together
Both companies are identified as members of the same industry group.
-
AngioDynamics (United States) Mentioned together
Both companies are members of the Medical - Instruments industry sector.
-
HCA Corporation Mentioned together
The evidence only places HCA Corporation within the Hospital industry, showing no direct relationship or coupling with Incepta Pharmaceuticals.
-
Cardinal Health Shared context
The evidence provided does not describe any relationship or coupling between Incepta Pharmaceuticals and Cardinal Health.
-
Armata Pharmaceuticals (United States) Shared context
Evidence only confirms Armata Pharmaceuticals belongs to a specific industry group, showing no direct coupling with Incepta Pharmaceuticals.
-
Dexcom Mentioned together
No evidence was provided linking Dexcom and Incepta Pharmaceuticals.
-
ADMA Biologics (United States) Mentioned together
The evidence only describes ADMA Biologics' membership in a specific industry group.
-
Abbott Laboratories Shared context
The provided evidence only describes Abbott's industry context and does not mention Incepta Pharmaceuticals.
-
Tenet Healthcare Shared context
The evidence provided describes Tenet Healthcare's industry context but does not mention Incepta Pharmaceuticals.
-
Ensign Records Shared context
The evidence describes Ensign Records' operations within the nursing homes industry, but does not detail any relationship with Incepta Pharmaceuticals.
-
Amgen Shared context
The evidence only places Amgen within the broader Medical sector, providing no direct coupling or relationship with Incepta Pharmaceuticals.
-
Astellas Pharma Mentioned together
The evidence does not describe any relationship between Incepta Pharmaceuticals and Astellas Pharma.
-
McKesson Corporation Mentioned together
The evidence provided focuses solely on McKesson Corporation's industry performance and does not describe a relationship with Incepta Pharmaceuticals.
History
Events by the month they beganJune 2026
42 events- Tilray Brands, Inc.'s stock change lagged the S&P 500 gain on August 28, 2025, while the company holds a Zacks Rank of #3.
- Precision BioSciences and Incepta Pharmaceuticals were noted as belonging to a specified industry in August 2025.
- LENZ Therapeutics shares outperformed industry average over the past week, following company developments.
- China's volume-based procurement policies are impacting pharmaceutical companies like Incepta and Envista.
- Recursion Pharmaceuticals experienced a decline on June 21, 2025, which lagged the losses of the S&P 500. The company was also placed into an industry group.
- Tilray Brands, Inc. showed higher growth than S&P 500 on June 21, 2025, and outperformed industry averages in short-term price activity.
- Viking Therapeutics and Incepta Pharmaceuticals are facing market scrutiny as their stock performance is compared against the S&P 500 and broader medical sector trends.
- Incepta Pharmaceuticals, Ensign Records, and Boston Scientific were classified into various medical industry groups in June 2025.
- On June 26, 2025, the Medical sector gain outperformed Humacyte's stock drop, with the cause traced to changes in the Zacks rating system.
- Siga Technologies stock underperformed the S&P 500 gain but led the Medical sector gain on July 25, 2025.
- HSIC's Price-to-Earnings ratio was reported to be lower than the industry average on June 30, 2025.
- Companies like Akero Therapeutics, Inc., Incepta Pharmaceuticals, and Aveanna Healthcare are noted for outperforming peers in the Medical sector.
- DaVita HealthCare outperformed S&P 500 daily loss and gained on the broader medical sector on July 2, 2025.
- Bayer Aktiengesellschaft and Dexcom were classified within the Large Cap Pharmaceuticals and Medical sectors, with Dexcom showing strong performance.
- Amgen's monthly gain underperformed the Medical sector's gain, while operating in the biomedical and genetics industry.
- Anavex Life Sciences (AVXL) received a Momentum Style Score of A and a Zacks Rank of #2 on July 11, 2025.
- Incepta Pharmaceuticals and Molina Healthcare were ranked in the bottom 33% of the industry as of July 12, 2025.
- On July 12, 2025, Moderna's stock drop lagged the S&P 500's daily loss, while the company outperformed the losses of the broader medical sector.
- Incepta Pharmaceuticals and West Pharmaceutical Services operate within the medical supplies sector.
- Incepta Pharmaceuticals and Delcath Systems, Inc. are involved in a new industry ranking.
- Incepta Pharmaceuticals, BioNTech SE Sponsored ADR, and EUROFINS SCIENT were noted for outperforming their peers in the Medical sector on July 24, 2025.
- Cardiff Oncology, a company in the medical/biomedical sector, underperformed the broader market index on July 30, 2025.
- Incepta Pharmaceuticals and Amphastar Pharmaceuticals were ranked in the Generic Drugs industry.
- Kiniksa Pharmaceuticals International, plc (KNSA) shares outperformed industry peers significantly on August 6, 2025.
- Fortrea Holdings Inc. was noted for underperforming the market index this year, while Incepta Pharmaceuticals belongs to the relevant industry sector.
- Phathom Pharmaceuticals, which operates in the Zacks Medical - Biomedical and Genetics industry, has been noted for underperforming the S&P 500 so far this year.
- Seer, Inc., a biomedical company, underperformed the S&P 500 this year, operating within the sector while Zacks Rank tracks earnings revisions.
- The company, Incepta Pharmaceuticals, was noted to belong to a specific industry as of August 7, 2025.
- AnaptysBio outperformed the market index on August 7, 2025, while the company was noted to be in a specific industry sector.
- Incepta Pharmaceuticals and Niagen Bioscience outperformed market gains this year, with investors using Zacks Rank to track earnings revisions.
- Urogen Pharma was classified in the Zacks Medical - Biomedical and Genetics industry and outperformed the S&P 500 stock gain this year.
- Eton Pharmaceuticals outperformed the S&P 500 this year and belongs to the relevant industry.
- Generation Bio Co. underperformed the market index while Incepta Pharmaceuticals was noted as being in the relevant industry sector.
- On August 13, 2025, the Price-to-Earnings ratio of Incepta Pharmaceuticals was noted to match that of Cardinal Health.
- Incepta Pharmaceuticals and Novavax were mentioned in a report on August 13, 2025, noting that industry performance influences stock trends.
- Incepta Pharmaceuticals and BioCryst Pharmaceuticals were ranked in the Medical – Drugs industry as of August 13, 2025.
- Incepta Pharmaceuticals and Catalyst Pharmaceuticals were mentioned in a recent report.
- On August 13, 2025, Orchestra BioMed Holdings, Inc. underperformed market gains while Incepta Pharmaceuticals was noted as being in the relevant industry sector.
- Alpha Cognition Inc. outperformed the market index on August 15, 2025, and investors can rely on Zacks Rank for tracking revisions.
- Black Diamond Therapeutics and BioRestorative Therapies, Inc. showed strong stock performance compared to the medical sector average in August 2025.
- Incepta Pharmaceuticals and Hologic are companies, with Hologic operating in the Medical - Instruments industry.
- Incepta Pharmaceuticals and Becton Dickinson were ranked in an industry as of August 2025.